Hormonal

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Pfizer will talk to regulators about pivotal study designs in cachexia following promising ponsegromab Phase II data, with results from a separate study in heart failure also coming soon.

The company said the results did not meet the threshold for continued capital investment, giving a boost to Spruce Biosciences and its competing congenital adrenal hyperplasia program.

The follow-on Cushing’s product relacorilant has hit in Phase III, and is forecast to lead the market – eventually.